A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.
Berenson, James R
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Feb 2009 - 1069-75 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
1078-0432
10.1158/1078-0432.CCR-08-1261 doi
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Boronic Acids--administration & dosage
Bortezomib
Combined Modality Therapy
Drug Administration Schedule
Ethylenediamines--administration & dosage
Humans
Maximum Tolerated Dose
Multiple Myeloma--therapy
Organophosphonates--administration & dosage
Platelet Count
Pyrazines--administration & dosage
Radioisotopes--administration & dosage
Recurrence
Samarium--administration & dosage
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Feb 2009 - 1069-75 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
1078-0432
10.1158/1078-0432.CCR-08-1261 doi
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Boronic Acids--administration & dosage
Bortezomib
Combined Modality Therapy
Drug Administration Schedule
Ethylenediamines--administration & dosage
Humans
Maximum Tolerated Dose
Multiple Myeloma--therapy
Organophosphonates--administration & dosage
Platelet Count
Pyrazines--administration & dosage
Radioisotopes--administration & dosage
Recurrence
Samarium--administration & dosage